6 results about "Human Thrombin" patented technology

Provided are a method for preparing high-purity and low-residue recombinant human thrombin and a use thereof. Specifically, a process for using genetically engineered cells to produce recombinant human thrombin is optimized. By means of process optimization and quality control for rEcarin process enzyme, which is a key raw material, the expression efficiency and purity of a recombinant protein are improved, the amount of residual impurities is reduced, and the safety risk of a topical recombinant human thrombin product is reduced, thereby ensuring the medication safety and stable continuous production of topical recombinant human thrombin.

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.

The invention relates to the field of biological medicine, in particular to an antithrombin III determination kit and a preparation method thereof. The antithrombin III determination kit comprises a reagent 1, a reagent 2, an ATIII calibration product and an ATIII quality control product. The reagent 1 is prepared from a Tris-HCl buffer solution, calcium chloride, bovine serum albumin, potassium ferrocyanide, gentamicin sulfate, ProClin 300, recombinant human thrombin and a nano blocking agent; the reagent 2 is prepared from a Tris-HCl buffer solution, S-2238, gentamicin sulfate and ProClin 300; the ATIII calibrator is prepared from a synthetic plasma matrix, recombinant human ATIII, natural ATIII, ProClin 300, a blood coagulation inhibitor, protamine and trehalose; the ATIII quality control product is prepared from a synthetic plasma matrix, recombinant human ATIII, natural ATIII, ProClin 300, a blood coagulation inhibitor, trehalose and mannitol, according to the scheme, the method is suitable for a full-automatic blood coagulation analysis platform and conforms to the development trend of in-vitro diagnostic reagents.

The invention relates to a method for rapidly detecting the activity of human thrombin in a human prothrombin complex, and belongs to the technical field of biological product detection. The method comprises the following steps: diluting a human thrombin solution into a plurality of gradients in equal proportion, then adding a fibrinogen solution, standing for a period of time, observing whether clots or fibrin are separated out, and determining the corresponding human thrombin activity titer limit when the clots or fibrin are separated out; mixing the human prothrombin complex with a fibrinogen solution, and detecting the refractive index under the wavelength of 589 nm; and determining the activity of the human thrombin in the human prothrombin complex by comparing the refractive index values. According to the method, the original 24-hour test time is shortened to be within 1 hour, and the problem that the time of an existing method for testing the activity of the human thrombin in the human prothrombin complex is too long is solved.

The invention belongs to the technical field of biology, and particularly relates to an anti-human thrombin-antithrombin complex antibody and a preparation method and application thereof and a preparation method of an anti-human thrombin-antithrombin complex (TAT), and the preparation method is characterized by comprising the following steps: (1) expressing and purifying human prothrombin (PT) and human antithrombin III (AT-III); (2) activating PT by using Ecarin snake venom to obtain thrombin (T); and (3) mixing T and AT-III according to a mass ratio of 0.7: 1 for reaction, and purifying to obtain the TAT complex, the invention also comprises a monoclonal antibody secreted by a hybridoma cell strain TAT-2F for specific recognition of TAT and a monoclonal antibody secreted by a hybridoma cell strain T-5B for specific recognition of T and TAT, and the monoclonal antibody provided by the invention can be combined with TAT with high specificity, so that the TAT complex can be used for detecting TAT and TAT. Therefore, the monoclonal antibody can be used for identifying or detecting a patient with abnormal blood coagulation.

The present disclosure is directed to human protease activated receptor 4 (PAR4) binding proteins (e.g. antibodies). In particular, anti-PAR4 binding proteins which are antagonists of human PAR4, as well as methods and uses thereof.